|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||95.20 - 98.00|
|52-week range||73.00 - 125.00|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The U.S. FDA accepted PharmaEssentia's resubmission for approval of ropeginterferon alfa-2b-njft to treat PV, with a new PDUFA date of Nov 13, 2021.
PharmaEssentia has resubmitted an application to the US FDA seeking approval for ropeginterferon alfa-2b-njft to treat PV, a rare blood cancer.
PharmaEssentia welcomes Dr. Norio Komatsu, renowned expert in MPN research in Japan, as Chairperson and Executive Director of our Japanese subsidiary.